Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...
Rigel Pharmaceuticals on Thursday said the U.S. Food and Drug Administration granted orphan-drug designation to its proposed R289 treatment for myelodysplastic syndromes, a group of rare blood cancers ...
Rigel Pharmaceuticals (RIGL) announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to R289 for the treatment ...
1d
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has ...
Rigel Pharmaceuticals (RIGL) announced the FDA has granted Orphan Drug designation to R289 for the treatment of myelodysplastic ...
Rigel Pharmaceuticals has shown significant growth, particularly from the acquisition of pralsetinib. Read why RIGL stock is ...
SOUTH SAN FRANCISCO, Calif., Jan. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals ...
Rigel Pharmaceuticals has a 12 month low of $7.48 and a 12 month high of $29.82. The firm has a market capitalization of $305.09 million, a PE ratio of 123.72 and a beta of 1.22. About Rigel ...
Fostamatinib disodium is under clinical development by Rigel Pharmaceuticals and currently in Phase III for Coronavirus Disease 2019 (COVID-19).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback